

Achillion Pharmaceuticals

[View the current Achillion Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/85-Achillion+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bi corporate/85-Achillion+Pharmaceuticals.html>)

Contact Details:

**300 George Street
New Haven**

Tel: (203) 624 7000

Fax: (203) 624 7003

Email: keastwood@achillion.com

06511

United States of America

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.

Product Candidate Portfolio

The Company's broad drug development pipeline includes antiviral compounds licensed from Yale University as well as those developed using our proprietary Zinc Finger Targeting (ZFT) technology. Achillion focuses on developing drugs to treat diseases caused by:

- Human immunodeficiency virus (HIV)
- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV) • Herpes viruses
- Bacteria
- Fungi

Recent Publications by Achillion Pharmaceuticals:



- [Internal cleavages of hepatitis C virus NS3 induced by P1 mutations at the NS3/4A cleavage site.](#)
*Despite being the focus of intensive investigation for its enzymatic...*28th November, 2008
Antiviral Drug Discovery, Achillion Pharmaceuticals, Inc., 300 George- Virology. 2008 Nov 24. ([DOI Direct Link](#))
- [THE EFFECT OF A SINGLE-DOSE OF RITONAVIR ON THE PHARMACOKINETIC BEHAVIOUR OF ELVUCITABINE, A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, WHEN ADMINISTERED IN HEALTHY VOLUNTEERS.](#)
*Purpose: To determine the effect of a single dose of 300 mg of ritonavir...*19th November, 2008

Faculte de Pharmacie, University of Montreal, Montreal, Canada; Achillion- Antimicrob Agents Chemother. 2008 Nov 17. ([DOI Direct Link](#))

- [THE MULTIPLE-DOSE PHARMACOKINETIC BEHAVIOUR OF ELVUCITABINE, A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, WHEN ADMINISTERED OVER 21 DAYS WITH LOPINAVIR/RITONAVIR IN HIV-1 SUBJECTS.](#)
*Purpose: To describe the plasma pharmacokinetics (PK) of elvucitabine at...*19th November, 2008
Faculte de Pharmacie, University of Montreal, Montreal, Canada; Achillion- Antimicrob Agents Chemother. 2008 Nov 17. ([DOI Direct Link](#))
- [Studying HCV RNA synthesis in vitro with replication complexes.](#)
*HCV replication complexes are well-organized protein and lipid structures...*15th November, 2008
Achillion Pharmaceuticals, New Haven, CT, USA.- Methods Mol Biol. 2009;510:177-84. ([DOI Direct Link](#))
- [A highly sensitive and reproducible HCV RNA hybridization method valuable for antiviral drug discovery.](#)
*Real-time RT-PCR and Northern blot are employed for the measurement of HCV...*20th September, 2008
Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.- J Virol Methods. 2008 Jul;151(1):154-7. Epub 2008 May 8. ([DOI Direct Link](#))
- [Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.](#)
*We have discovered a novel class of compounds active against hepatitis C...*17th July, 2008
Achillion Pharmaceuticals, New Haven, CT 06511, USA.- Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52. Epub 2008 Apr 14. ([DOI Direct Link](#))
- [Recent advances in bacterial topoisomerase inhibitors.](#)
*Bacterial topoisomerase inhibitors continue to be actively developed as...*17th June, 2008
Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511,- Curr Opin Pharmacol. 2008 Oct;8(5):574-81. Epub 2008 Jun 12. ([DOI Direct Link](#))
- [A method to assay penicillin-binding proteins.](#)
*Key enzymes that assemble the bacterial cell wall are also the target of...*23rd May, 2008
Achillion Pharmaceuticals, New Haven, CT, USA.- Methods Mol Med. 2008;142:131-41. ([DOI Direct Link](#))
- [Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.](#)
*Heteroaryl isothiazolones (HITZs) are antibacterial agents that display...*31st October, 2007
Achillion Pharmaceuticals, New Haven, CT 06511, USA.- Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. Epub 2007 May 14. ([DOI Direct Link](#))
- [Novel genetic techniques and approaches in the microbial genomics era: identification and/or validation of targets for the discovery of new antibacterial agents.](#)
*The availability of microbial genome sequences has ushered in the genomics...*12th October, 2007
Achillion Pharmaceuticals Inc, New Haven, CT 06511, USA.- Drugs R D. 2007;8(4):201-12.
- [Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp.](#)
*A novel 5,4-dialkyl substituted thiophene was discovered by in silico...*25th September, 2007
Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.- Bioorg Med Chem Lett. 2007 Jul 15;17(14):3905-9. Epub 2007 May 3. ([DOI Direct Link](#))
- [In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.](#)
*The activities of several tricyclic heteroaryl isothiazolones (HITZs)...*2nd August, 2007
Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.- Antimicrob Agents Chemother. 2007 Apr;51(4):1259-67. Epub 2007 Jan 22. ([DOI Direct Link](#))
- [Small molecule inhibitors of E. coli primase, a novel bacterial target.](#)
*Bacterial primase is essential for DNA replication in Gram-positive and...*31st July, 2007
Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.- Bioorg Med Chem Lett. 2007 May 15;17(10):2807-10. Epub 2007 Feb 25. ([DOI Direct Link](#))

- [Hepatitis C virus \(HCV\) NS5B nonnucleoside inhibitors specifically block single-stranded viral RNA synthesis catalyzed by HCV replication complexes in vitro.](#)
*Replication complexes of hepatitis C virus synthesized two major species...*3rd July, 2007
Achillion Pharmaceuticals, 300 George Street, New Haven, CT 06511, USA.- Antimicrob Agents Chemother. 2007 Jan;51(1):338-42. Epub 2006 Nov 6. ([DOI Direct Link](#))
- [Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.](#)
*We describe the biological evaluation of isothiazoloquinolones (ITQs)...*10th March, 2007
Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, Connecticut- J Med Chem. 2007 Jan 25;50(2):199-210. ([DOI Direct Link](#))

BioNews Results for Achillion Pharmaceuticals



- [Achillion to Present At Lazard Capital Markets 5th Annual Healthcare Conference](#)
Pharma Live: Nov 17 2008 5:08PM Matching: achillion pharmaceuticals
- [Achillion to Present At Lazard Capital Markets 5th Annual Healthcare Conference](#)
Therapeutics Daily: Nov 17 2008 1:15PM Matching: achillion pharmaceuticals
- [Resisting Bug Resistance With New and Better Antibiotics](#)
Pharmacy Choice: Nov 17 2008 11:16PM Matching: achillion pharmaceuticals
- [Achillion Pharmaceuticals, Inc. - SWOT Analysis - <http://www.companiesandmarkets.com> adds new report](#)
PR inside: Oct 30 2008 9:06AM Matching: achillion pharmaceuticals
- [Oppenheimer Downgrades Achillion Pharma \(ACHN\) to Perform](#)
Street Insider: Oct 30 2008 6:35PM Matching: achillion pharmaceuticals
- [Achillion Reports Third Quarter 2008 Financial Results](#)
Pharma Live: Oct 29 2008 11:49AM Matching: achillion pharmaceuticals
- [Achillion Reports Third Quarter 2008 Financial Results](#)
NewsBlaze: Oct 29 2008 1:12AM Matching: achillion pharmaceuticals
- [Data From Achillion's Antibacterial and HIV Programs Presented At the 2008 ICAAC/IDSA Joint Meeting](#)
Pharma Live: Oct 28 2008 10:41PM Matching: achillion pharmaceuticals
- [Achillion Reports Third Quarter 2008 Financial Results](#)
Stockwatch: Oct 28 2008 8:51PM Matching: achillion pharmaceuticals
- [Achillion Reports Third Quarter 2008 Financial Results](#)
MarketWatch: Oct 28 2008 9:08PM Matching: achillion pharmaceuticals
- [Achillion Reports Third Quarter 2008 Financial Results](#)
Yahoo! Canada: Oct 28 2008 10:41PM Matching: achillion pharmaceuticals
- [Data From Achillion's Antibacterial and HIV Programs Presented At the 2008 ICAAC/IDSA Joint Meeting](#)
NewsBlaze: Oct 27 2008 11:49PM Matching: achillion pharmaceuticals
- [Achillion Reports Third Quarter 2008 Financial Results](#)
Therapeutics Daily: Oct 28 2008 9:23PM Matching: achillion pharmaceuticals
- [No significant differences between elvucitabine and 3TC at 48 weeks](#)
Aidsmap: Oct 27 2008 11:47AM Matching: achillion pharmaceuticals



Achillion Pharmaceuticals Patents:

- 7439374- [Azabenzofuran substituted thioureas; inhibitors of viral replication](#)
- 7365068- [Substituted aryl acylthioureas and related compounds; inhibitors of viral replication](#)
- 7199128- [8-N-substituted-2H-isothiazolo\[5,4-b\]quinolizine-3,4-diones and related compounds as antiinfective agents](#)
- 7094807- [Substituted aryl thioureas and related compounds; inhibitors of viral replication](#)
- 6897302- [Method for synthesizing .beta.-L-5-fluoro-2',3'-dideoxy-2',3'-dideohydrocytidine \(.beta.-L-FD4C\)](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

